PMID- 30556873
OWN - NLM
STAT- MEDLINE
DCOM- 20200113
LR  - 20200113
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 22
IP  - 23
DP  - 2018 Dec
TI  - Long non-coding RNA FENDRR inhibits NSCLC cell growth and aggressiveness by 
      sponging miR-761.
PG  - 8324-8332
LID - 16530 [pii]
LID - 10.26355/eurrev_201812_16530 [doi]
AB  - OBJECTIVE: The aim of this paper is to investigate the functions of long 
      noncoding RNA (lncRNA) FOXF1 Adjacent Non-Coding Developmental Regulatory RNA 
      (FENDRR) in the growth and aggressiveness of non-small cell lung cancer (NSCLC). 
      PATIENTS AND METHODS: The expression of FENDRR in NSCLC tissues and cell lines 
      was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). 
      3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) and 
      colony formation assays were conducted to explore the roles of FENDRR on the 
      growth of NSCLC cell. The wound healing and transwell invasion assays were 
      conducted to explore the impact of FENDRR on NSCLC cell migration and invasion. 
      The apoptosis of NSCLC cell was detected using flow cytometer-based Annexin 
      V/Propidium Iodide (PI) dual staining. The xenograft model was conducted to 
      investigate the effect of FENDRR on the growth of NSCLC cell in vivo. The 
      expression of Ki67 was measured by immunohistochemical (IHC) staining using Ki67 
      antibody. Bioinformatics analysis and Luciferase reporter assay were applied to 
      identify that miR-761 was the target of FENDRR. Additional, colony formation and 
      transwell experiments were utilized to confirm that FENDRR inhibited the growth 
      and aggressiveness of NSCLC cell by regulating miR-761. RESULTS: We found a 
      marked down-regulation of FENDRR in NSCLC tissues compared to tumor-adjacent 
      tissues. FENDRR down-expression was detected in four NSCLC cell lines (H1650, 
      HCC827, H1975 and A549) compared to the human non-tumorigenic bronchial 
      epithelial cell, BEAS-2B. Low expression of FENDRR was identified as a predictive 
      factor for poor prognosis of patients with NSCLC. The over-regulation of FENDRR 
      inhibited the proliferation, migration and invasion capacities of NSCLC cell and 
      promoted the apoptosis of NSCLC cell in vitro whereas the down-regulation of 
      FENDRR caused the opposite results. Moreover, the over-expression of FENDRR 
      restrained the growth of NSCLC cell in vivo. We found that there were potential 
      binding sites between FENDRR and miR-761 and the level of miR-761 was inversely 
      associated with the expression of ENDRR in NSCLC tissues. Finally, the rescue 
      experiments suggested that the anti-oncogenic role of FENDRR was at least 
      partially mediated by miR-761 in NSCLC. CONCLUSIONS: We found that FENDRR was 
      down-expressed in NSCLC and the over-expression of FENDRR inhibited the malignant 
      phenotypes of NSCLC cell by binding to miR-761 competitively.
FAU - Zhang, M-Y
AU  - Zhang MY
AD  - Department of Thoracic Surgery, Affiliated Hospital of Weifang Medical 
      University, Weifang, China. fulinfulinfl@163.com.
FAU - Zhang, Z-L
AU  - Zhang ZL
FAU - Cui, H-X
AU  - Cui HX
FAU - Wang, R-K
AU  - Wang RK
FAU - Fu, L
AU  - Fu L
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (MicroRNAs)
RN  - 0 (RNA, Long Noncoding)
RN  - 0 (microRNA761 microRNA, human)
SB  - IM
MH  - A549 Cells
MH  - Animals
MH  - Apoptosis
MH  - Binding Sites
MH  - Carcinoma, Non-Small-Cell Lung/genetics/*metabolism/pathology
MH  - *Cell Movement
MH  - *Cell Proliferation
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lung Neoplasms/genetics/*metabolism/pathology
MH  - Mice, Nude
MH  - MicroRNAs/genetics/*metabolism
MH  - Neoplasm Invasiveness
MH  - RNA, Long Noncoding/genetics/*metabolism
MH  - Signal Transduction
EDAT- 2018/12/18 06:00
MHDA- 2020/01/14 06:00
CRDT- 2018/12/18 06:00
PHST- 2018/12/18 06:00 [entrez]
PHST- 2018/12/18 06:00 [pubmed]
PHST- 2020/01/14 06:00 [medline]
AID - 16530 [pii]
AID - 10.26355/eurrev_201812_16530 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8324-8332. doi: 
      10.26355/eurrev_201812_16530.